Commentary & Reports For: (OTCQB: ACTC), (OTCQB: FNMA)
Advanced Cell Technology, Inc. (OTCQB: ACTC) Robert Lanza, M.D., chief scientific officer of ACTC recently stated “They offer the possibility to generate a non-controversial, unlimited source of patient-specific stem cells without embryo destruction. Owing to their short storage time, there is a constant demand for this life-saving blood component. Since platelets don’t contain any genetic material, they cannot form tumors, which makes them ideal for the first clinical trial involving the iPS cell technology. We hope to initiate the first...
View full press release